RT Journal Article
T1 Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoE−/− Mice Experimental Model
A1 Ruiz-Roso Guerra, María Belén
A1 Echeverry Alzate, Víctor
A1 Ruiz-Roso Calvo de la Mora, Baltasar
A1 Quintela, José
A1 Ballesteros Rodrigálvarez, Sandra
A1 Lahera Julia, Vicente
A1 Heras Jiménez, Natalia de las
A1 López Moreno, José Antonio
A1 Martín Fernández, Beatriz
AB Alzheimer’s disease (AD) is the main cause of dementia and cognitive impairment. It has been associated with a significant diminution of omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) levels in the brain. Clinical trials with DHA as a treatment in neurological diseases have shown inconsistent results. Previously, we reported that the presence of phytanic acid (PhA) in standard DHA compositions could be blunting DHA’s beneficial effects. Therefore, we aimed to analyze the effects of a low PhA-concentrated DHA and a standard PhA-concentrated DHA in Apolipoprotein E knockout (ApoE
PB MDPI
SN 2072-6643
YR 2018
FD 2018
LK https://hdl.handle.net/20.500.14352/19079
UL https://hdl.handle.net/20.500.14352/19079
LA eng
NO Ministerio de Ciencia e Innovación (MICINN)
NO Fondo de Investigación Sanitaria (Red de Trastornos Adictivos, FEDER)
DS Docta Complutense
RD 7 may 2024